Emma Guttman, MD, PhD, FAAD, Joshua Zeichner, MD, FAAD
Emma Guttman, MD talks to DermTube Journal Club Host Josh Zeichner, MD about topical and systemic treatments in the pipeline that are offering patients with atopic dermatitis new hope. With a greater understanding of the underlying causes of atopic dermatitis, targeted biologic treatments, such as dupilumab, are being investigated. Dr. Guttman offers insight into the dupilumab clinical trials, and says she is hopeful it will be FDA approved soon. She also discusses a topical phosphodiesterase-4 inhibitor that is also expected to receive FDA approval soon.